We use both our own and third-party cookies for statistical purposes and to improve our services. If you continue to browse, we consider that you accept the use of these.

Our Story

Empowering Personalized
Medicine Through RNA

WHO IS COFACTOR?

Cofactor Genomics was founded after the pioneering efforts of the Human Genome Project made high-throughput, affordable human genome sequencing a reality. The founders saw that analyzing RNA offered a number of advantages over the static nature of DNA (learn more here).

 

Today, Cofactor works in partnership with medical centers, pharma companies, and clinical research organizations to offer the most advanced machine-learning tools, deep databases, and molecular reagents through our Predictive Immune Modeling platform which enables us to match patients with the therapies that will benefit them the most.
INVESTORS

ADVANCING PRECISION MEDICINE

Despite major breakthroughs in cancer treatments, less than 20% of patients respond to even the most innovative immunotherapies. The reason is the industry’s reliance on imperfect, single-analyte biomarkers – using antiquated methods to poorly match patients to therapies.

Our team of 20-year veterans in genomics have harnessed the power of RNA to build the technologies, data assets, and regulatory frameworks to enable more predictive multidimensional biomarkers. Driven by clinical and market data, we’ve prioritized a list of key cancer subtypes that address the highest unmet clinical need, with promising results.

OUR TECHNOLOGY

CREATIVE, SCIENTIFIC, DRIVEN

Our team is as multifaceted as the biomarkers we’re building. With scientific experts, computer science wizards, and creative individuals abound, we’re determined to solve the challenges that have stalled precision medicine. We move quickly, experiment regularly, and make time to enjoy each other’s company. We’d love to hear how your background fits with our mission.
JOIN OUR TEAM

LEADERSHIP

  • Jarret Glasscock, PhD
    Jarret Glasscock, PhD Founder and CEO

    20 years leading RNA-based Genomic Research. 10 years on the Human Genome Project. PhD in Computational Biology.

  • Jon Armstrong
    Jon Armstrong CSO

    18 years developing DNA/RNA sequencing technologies and applications. 9 years Technology Development at Washington University Genome Institute. Developed molecular kits to run on Illumina/Solexa Serial #1.

  • Dave Messina
    Dave Messina COO

    20 years in Genomics. Masters in Genetics, PhD in Computational Biology. Led Cofactor’s CAP-CLIA accreditation team.

  • Natalie LaFranzo, PHD
    Natalie LaFranzo, PHD VICE PRESIDENT, MARKET DEVELOPMENT

    Broad commercial background spanning sales, marketing, product development and management of genomics assays and reference materials.

  • Eric Duncavage, MD
    Eric Duncavage, MD Medical Director

    Board certified Clinical Diagnostic Pathologist, co-directs clinical assay development at the Washington University, member of the clinical laboratory standards institute (CLSI).

SUPPORTED BY

INVESTOR INQUIRIES

[email protected]

PRESS INQUIRIES

[email protected]

Cofactor offers products both for Research Use Only (not to be used as a diagnostic assay) and within our CAP-certified laboratory.  Please contact us to discuss which option is right for your application.

Learn more about our offerings.

IMMUNOPRISM ASSAY
RNA SEQUENCING